Lyell Immunopharma, Inc. (LYEL) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Lyell Immunopharma, Inc. (LYEL) Healthcare & Pipeline Overview

Lyell Immunopharma, Inc. is a T cell reprogramming company developing innovative therapies for solid tumors, leveraging its Gen-R and Epi-R platforms to overcome T cell exhaustion and enhance stemness. The company's pipeline targets cancers like non-small cell lung cancer and triple-negative breast cancer, positioning it within the competitive biotechnology landscape.

What Is the Investment Thesis for LYEL?

Lyell Immunopharma's investment thesis centers on its innovative T cell reprogramming technologies, Gen-R and Epi-R, which aim to address the critical challenges of T cell exhaustion and durability in solid tumors. The company's pipeline, including LYL797 and LYL845, targets large oncology markets with significant unmet needs. A key value driver is the potential for these therapies to demonstrate superior efficacy and durability compared to existing treatments, leading to increased market share and revenue growth. The collaboration with GlaxoSmithKline for the NY-ESO-1 program provides validation of Lyell's technology and potential for future partnerships. However, the company's high negative profit margin of -794858.1% and gross margin of -7422.6% highlight the risks associated with early-stage biotechnology companies, including clinical trial failures and regulatory hurdles. Upcoming clinical trial results for LYL797 and LYL845 will be critical catalysts for the stock. The company's market capitalization of $376M reflects both the potential and the risks associated with its innovative approach.

Based on FMP financials and quantitative analysis

LYEL Key Highlights

Lyell Immunopharma is pioneering T cell reprogramming technologies, Gen-R and Epi-R, targeting solid tumors.

• The company's lead product candidate, LYL797, is in development for non-small cell lung cancer and triple-negative breast cancer, addressing significant unmet needs.
• Lyell has a research and development collaboration with GlaxoSmithKline for the NY-ESO-1 program, validating its technology and providing potential revenue streams.
• The company's market capitalization is $0.56 billion, reflecting investor expectations for its innovative therapies.
• Lyell's negative profit margin of -794858.1% and gross margin of -7422.6% highlight the high-risk, high-reward nature of the biotechnology industry.

Who Are LYEL's Competitors?

LYEL is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are LYEL's Key Strengths?

Innovative T cell reprogramming technologies (Gen-R and Epi-R).

• Pipeline of T cell therapy candidates targeting solid tumors.
• Collaboration with GlaxoSmithKline.
• Experienced management team.

What Are LYEL's Weaknesses?

Early-stage biotechnology company with no commercial products.

• High research and development costs.
• Dependence on clinical trial success and regulatory approvals.
• Negative profit and gross margins.

What Could Drive LYEL Stock Higher?

Clinical trial results for LYL797 in non-small cell lung cancer and triple-negative breast cancer.

• Clinical trial results for LYL845 in multiple solid tumors.
• Progress in the collaboration with GlaxoSmithKline on the NY-ESO-1 program.
• Expansion of the pipeline with new T cell therapy candidates.
• Strategic partnerships and collaborations with other pharmaceutical companies.

What Are the Key Risks for LYEL?

Financial-distress signal — its Altman Z-Score of -6.57 sits in the distress zone (elevated bankruptcy risk).

• Negative return on equity (-91.6%) — the business is not currently generating profit on shareholder capital.
• Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
• Clinical trial failures for LYL797 and LYL845.
• Regulatory hurdles in obtaining approvals for T cell therapies.
• Competition from other cancer therapies.
• High research and development costs.
• Patent challenges to Lyell's intellectual property.

What Are the Growth Opportunities for LYEL?

• Growth opportunity 1: Expansion of LYL797 into additional indications beyond non-small cell lung cancer and triple-negative breast cancer. The global market for lung cancer therapeutics is projected to reach $45.9 billion by 2027, while the market for breast cancer therapeutics is expected to reach $38.4 billion by 2027. Successful clinical trials and regulatory approvals in these additional indications would significantly expand Lyell's addressable market and revenue potential. This expansion could occur within the next 3-5 years, contingent on clinical trial outcomes.
• Growth opportunity 2: Development and commercialization of LYL845 for multiple solid tumors. This broadens Lyell's therapeutic scope and diversifies its revenue streams. The market for solid tumor therapies is vast, encompassing a wide range of cancer types. Lyell's competitive advantage lies in its ability to reprogram T cells to overcome the challenges of the tumor microenvironment, potentially leading to more effective and durable responses. Commercialization could begin within 5-7 years, pending clinical trial success and regulatory approvals.
• Growth opportunity 3: Strategic partnerships and collaborations with other pharmaceutical companies. Lyell's existing collaboration with GlaxoSmithKline demonstrates the value of its technology platform. Expanding these partnerships could provide additional funding, resources, and expertise to accelerate the development and commercialization of its therapies. These partnerships could also provide access to new markets and indications. New partnerships could materialize within the next 1-3 years.
• Growth opportunity 4: Advancement of the NY-ESO-1 program in collaboration with GlaxoSmithKline. This program targets synovial sarcoma and other solid tumor indications, providing another potential revenue stream for Lyell. The market for synovial sarcoma therapies is relatively small but underserved, offering an opportunity for Lyell to establish a strong presence in this niche market. Clinical trial progress and regulatory approvals could drive revenue growth within the next 3-5 years.
• Growth opportunity 5: Leveraging the Gen-R and Epi-R platforms to develop new T cell therapies for other cancer types. Lyell's technology platforms have the potential to be applied to a wide range of cancers, providing a pipeline of future product candidates. This would require ongoing research and development efforts, but could significantly expand Lyell's long-term growth potential. New product candidates could enter clinical trials within the next 5-7 years.

What Are LYEL's Competitive Advantages?

• Proprietary T cell reprogramming technologies (Gen-R and Epi-R) that enhance T cell functionality and durability.
• Strong intellectual property portfolio protecting its technologies and product candidates.
• Research and development expertise in T cell therapy and cancer immunotherapy.
• Collaboration with GlaxoSmithKline, providing validation and resources.

What Does LYEL Do?

Lyell Immunopharma, Inc. is a biotechnology company founded in 2018 and headquartered in South San Francisco, California, focused on revolutionizing the treatment of solid tumors through T cell reprogramming. Recognizing the limitations of existing T cell therapies, Lyell was established to address the challenges of T cell exhaustion and lack of durability in the tumor microenvironment. The company develops innovative T cell therapies using two primary technology platforms: Gen-R and Epi-R. Gen-R is an ex vivo genetic reprogramming technology designed to overcome T cell exhaustion, enabling T cells to maintain their cytotoxic activity for longer periods. Epi-R, on the other hand, is an ex vivo epigenetic reprogramming technology that generates a population of T cells with durable stemness, allowing them to self-renew and persist within the tumor. Lyell's pipeline includes LYL797, a T cell product candidate targeting non-small cell lung cancer and triple-negative breast cancers; LYL845, which targets multiple solid tumors; and NY-ESO-1 for synovial sarcoma and other solid tumor indications. The company has a research and development collaboration and license agreement with GlaxoSmithKline for the NY-ESO-1 program, expanding its reach and validating its technology. Lyell's commitment to innovation and its focus on overcoming the limitations of current T cell therapies position it as a key player in the evolving landscape of cancer immunotherapy.

What Products and Services Does LYEL Offer?

• Develop T cell therapies for solid tumors.
• Utilize Gen-R technology to overcome T cell exhaustion.
• Employ Epi-R technology to generate T cells with durable stemness.
• Develop LYL797 for non-small cell lung cancer and triple-negative breast cancers.
• Develop LYL845 for multiple solid tumors.
• Collaborate with GlaxoSmithKline on the NY-ESO-1 program for synovial sarcoma.

How Does LYEL Make Money?

• Develop and commercialize T cell therapies for solid tumors.
• Generate revenue through product sales and licensing agreements.
• Collaborate with pharmaceutical companies to develop and commercialize therapies.
• Focus on innovative T cell reprogramming technologies to improve efficacy and durability.

What Industry Does LYEL Operate In?

Lyell Immunopharma operates within the rapidly evolving biotechnology industry, specifically in the field of cancer immunotherapy. The market for cancer therapies is substantial and growing, driven by an aging population and increasing cancer incidence rates. T cell therapies, such as CAR-T cell therapy, have shown promise in hematological malignancies, but their application to solid tumors has been limited by challenges such as T cell exhaustion and the immunosuppressive tumor microenvironment. Lyell's focus on T cell reprogramming aims to overcome these limitations, positioning it to compete with other companies developing novel immunotherapies. Key competitors include companies developing CAR-T cell therapies, checkpoint inhibitors, and other immunomodulatory agents. The success of Lyell's therapies will depend on their ability to demonstrate superior efficacy and safety compared to existing and emerging treatments.

Who Are LYEL's Key Customers?

• Patients with solid tumors, including non-small cell lung cancer, triple-negative breast cancer, and synovial sarcoma.
• Hospitals and oncology clinics that administer T cell therapies.
• Pharmaceutical companies that partner with Lyell to develop and commercialize therapies.

Wall Street analysts project Lyell Immunopharma, Inc. revenue of about $11K for fiscal 2026, with EPS near $-7.64. The estimate reflects 7 contributing analysts.

Lyell Immunopharma, Inc. has beaten Wall Street's EPS estimate in 5 of its last 8 reported quarters — more hits than misses. Reported results have landed about 53.7% below estimates on average.

Lyell Immunopharma, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -6.57 places it in the distress zone, a signal of elevated financial risk.

Return on equity for Lyell Immunopharma, Inc. stands at -91.6%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -79.9%, showing how much profit it generates from its asset base. Its free cash flow yield is -47.9%, a gauge of the cash the business throws off relative to its market value. A current ratio of 5.36 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -72.3%, the inverse of the P/E and a quick read on earnings relative to price.

Lyell Immunopharma, Inc. (LYEL) Valuation Context

Valued at $376M, LYEL is classified as a small-cap stock. Relative to its peer group, LYEL's quantitative score of 9/100 is below the peer average of 81/100.

LYEL Revenue & Earnings Trend

In Q2 2026, LYEL generated $4K in top-line revenue, marking a sequential increase of 100.0%. The company recorded a net loss of $44.8M, with diluted EPS of $-1.92. Quarter-over-quarter revenue has been mixed, typical for a small-cap company operating in Healthcare. Across the four most recent quarters, LYEL averaged $-2.94 in diluted EPS.

Company Profile

Lyell Immunopharma, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in South San Francisco, US. The company is led by CEO Lynn Seely. LYEL has traded publicly since 2021.

LYEL Financials

LYEL Latest News

LYEL Analyst Consensus

LYEL MoonshotScore

LYEL Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources